Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(50%)
Results Posted
200%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_4
2
50%
Ph not_applicable
2
50%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)

Detailed Status

Recruiting1
Completed1
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 42 (50.0%)
N/A2 (50.0%)

Trials by Status

recruiting125%
completed125%
terminated125%
active_not_recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
active_not_recruitingphase_4

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

NCT05108558
recruitingphase_4

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

NCT06649539
completednot_applicable

Penile Length Maintenance Post-Prostatectomy

NCT03500419
terminatednot_applicable

Penile Lengthening Pre-Penile Prosthesis Implantation

NCT03500406

Clinical Trials (4)

Showing 4 of 4 trials
NCT05108558Phase 4

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

Active Not Recruiting
NCT06649539Phase 4

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

Recruiting
NCT03500419Not Applicable

Penile Length Maintenance Post-Prostatectomy

Completed
NCT03500406Not Applicable

Penile Lengthening Pre-Penile Prosthesis Implantation

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4